

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
9 April 2009 (09.04.2009)

PCT

(10) International Publication Number
WO 2009/044311 A1

(51) International Patent Classification:

C07D 333/38 (2006.01) A61P 35/00 (2006.01)
C07D 409/12 (2006.01) A61P 31/00 (2006.01)
A61K 31/425 (2006.01) A61P 29/00 (2006.01)
A61K 31/5377 (2006.01)

(21) International Application Number:

PCT/IB2008/053883

(22) International Filing Date:

24 September 2008 (24.09.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/997,882 5 October 2007 (05.10.2007) US

(71) Applicant (for all designated States except US): **ENCY-SIVE PHARMACEUTICALS INC.** [US/US]; Research and Development, 4848 Loop Center Drive 7th Floor, Houston, Texas 77081 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ANDERSON, Eric C.** [US/US]; Encysive Pharmaceuticals Inc., Research


and Development 4848 Loop, Center Drive 7th Floor, Houston, Texas 77081 (US). **DUPRE, Brian** [US/US]; Encysive Pharmaceuticals Inc., Research and Development 4848 Loop, Center Drive 7th Floor, Houston, Texas 77081 (US). **MARKET, Robert V.** [US/US]; Encysive Pharmaceuticals Inc., Research and Development 4848 Loop, Center Drive 7th Floor, Houston, Texas 77081 (US). **MONK, Keith A.** [US/US]; Encysive Pharmaceuticals Inc., Research and Development 4848 Loop, Center Drive 7th Floor, Houston, Texas 77081 (US). **SAVAGE, Michael M.** [US/US]; Encysive Pharmaceuticals Inc., Research and Development 4848 Loop, Center Drive 7th Floor, Houston, Texas 77081 (US).

(74) Agents: **FULLER, Grover, F., Jr.** et al.; Pfizer Inc., 235 East 42nd Street, New York, New York 10017 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,

[Continued on next page]

(54) Title: THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS MODULATORS OF CCR9 RECEPTOR



(57) Abstract: Provided are compounds of Formula (I) or of Formula (II) that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated with modulation of CCR9 receptor activity.





TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments